Overview

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of bulevirtide combination with pegylated interferon in participants with chronic hepatitis delta (CHD).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences
MYR GmbH

Collaborator:

Hepatera Ltd.

Treatments:

Interferon-alpha
Peginterferon alfa-2a